EMEA-001533-PIP01-13-M02
Key facts
Invented name |
Steglatro
|
Active substance |
Ertugliflozin
|
Therapeutic area |
Endocrinology, -gynacology-fertility-metabolism
|
Decision number |
P/0141/2019
|
PIP number |
EMEA-001533-PIP01-13-M02
|
Pharmaceutical form(s) |
Film-coated tablet
|
Condition(s) / indication(s) |
Treatment of type II diabetes mellitus
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Merck Sharp and Dohme (Europe), Inc.
Tel. +33 180464738 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|